Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)
NIH funding supports a four-center clinical research network to design, implement, and manage studies addressing pivotal clinical questions about antimicrobial resistance; a clinical trial is required.
This grant was recently updated
This grant has transitioned from forecasted to posted and is now accepting applications.
Funder: National Institutes of Health
Due Dates: November 10, 2026 (Application, 5:00 PM applicant organization’s local time)
Funding Amounts: $18 million committed for one award in FY 2027; budgets not expected to exceed $12 million direct costs annually; seven years
Summary: Supports an integrated clinical research network to improve prevention, diagnosis, and treatment of antimicrobial-resistant infections.
Key Information: Applications must propose clinical trials and include all four network centers.
Description
The National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, supports a coordinated Clinical Research Network (CRN) on antimicrobial resistance through a UM1 cooperative agreement. The network will design, implement, and manage clinical trials, studies, and related activities addressing pivotal questions in preventing, diagnosing, and treating bacterial and fungal infections. It integrates scientific leadership, clinical operations, laboratory services, and statistics and data coordination.
Research priorities include novel antimicrobials and combinations, non-antibiotic therapies, optimization of licensed treatments, and diagnostics that guide antimicrobial use or support regulatory approval. Particular emphasis is placed on difficult-to-treat Gram-negative infections. Additional interests include biomarkers, clinical informatics, molecular epidemiology, pharmacokinetic/pharmacodynamic studies, and advancement opportunities for early-career investigators and researchers entering AMR research.
